Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adicet Bio ( (ACET) ) has issued an update.
On December 19, 2025, Adicet Bio’s shareholders approved, and its board subsequently set, a 1-for-16 reverse stock split of the company’s common stock, which became effective at 12:01 a.m. Eastern Time on December 30, 2025. The move reduces Adicet’s outstanding shares from roughly 153.3 million to about 9.6 million without changing the 300 million authorized share count or the stock’s par value, while proportionally adjusting equity incentive plans, options and warrants; trading on the Nasdaq Capital Market began on a split-adjusted basis under the existing “ACET” ticker on December 30, 2025, with fractional share entitlements settled in cash. By shrinking the share count and boosting the per-share trading price, the reverse split is intended to help Adicet regain compliance with Nasdaq’s minimum bid price requirement and preserve its U.S. listing, a key consideration for existing shareholders and for the company’s future access to capital markets.
The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.
Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.
To see Spark’s full report on ACET stock, click here.
More about Adicet Bio
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, advancing an “off‑the‑shelf” pipeline of gamma delta T cells engineered with chimeric antigen receptors to deliver durable activity in patients.
Average Trading Volume: 2,619,286
Technical Sentiment Signal: Sell
Current Market Cap: $79.69M
For a thorough assessment of ACET stock, go to TipRanks’ Stock Analysis page.